Zhi Tong Cai Jing·2025-08-05 09:37Group 1 - The global enthusiasm for dual antibodies development is rising, creating an innovation achievement window for the domestic antibody industry [1] - Junshi Bioscience has extensive experience in monoclonal antibody development, with its PD-1 monoclonal antibody, Toripalimab, being one of the first domestically launched PD-1 inhibitors [1] - Toripalimab is currently approved for multiple indications in China and is expanding its global commercialization network, with approvals expected in the US and EU in 2023 and 2024 [1] Group 2 - Junshi Bioscience has developed a series of innovative dual antibodies (JS207, JS201, JS203, JS205) and dual antibody ADC (JS212) based on its monoclonal antibody foundation [1] - On June 20, Junshi Bioscience completed a placement of 41 million new shares, raising approximately HKD 1.026 billion [1] - The company plans to allocate 70% of the net proceeds from the placement for innovative drug research and development, including PD-1/VEGF dual antibodies and other pipeline projects [1]